195 related articles for article (PubMed ID: 28710511)
1. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
2. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
3. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler CA
Ann Neurol; 2019 Aug; 86(2):316-321. PubMed ID: 31148214
[TBL] [Abstract][Full Text] [Related]
4. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI; Herdlevaer I; Peter E; Haugen M; Totland C; Vedeler C
Eur J Neurol; 2023 Jun; 30(6):1727-1733. PubMed ID: 36912432
[TBL] [Abstract][Full Text] [Related]
5. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Herdlevaer I; Kråkenes T; Schubert M; Vedeler CA
Ann Clin Transl Neurol; 2020 Nov; 7(11):2231-2242. PubMed ID: 33009713
[TBL] [Abstract][Full Text] [Related]
6. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M; Panja D; Haugen M; Bramham CR; Vedeler CA
Acta Neuropathol; 2014 Dec; 128(6):835-52. PubMed ID: 25341622
[TBL] [Abstract][Full Text] [Related]
9. CDR2 antigen and Yo antibodies.
Totland C; Aarskog NK; Eichler TW; Haugen M; Nøstbakken JK; Monstad SE; Salvesen HB; Mørk S; Haukanes BI; Vedeler CA
Cancer Immunol Immunother; 2011 Feb; 60(2):283-9. PubMed ID: 21080165
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
12. Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue.
Raspotnig M; Kråkenes T; Herdlevær I; Haugen M; Vedeler C
J Neuroimmunol; 2022 Jan; 362():577766. PubMed ID: 34823119
[TBL] [Abstract][Full Text] [Related]
13. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
14. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
15. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique.
Monstad SE; Storstein A; Dørum A; Knudsen A; Lønning PE; Salvesen HB; Aarseth JH; Vedeler CA
Clin Exp Immunol; 2006 Apr; 144(1):53-8. PubMed ID: 16542365
[TBL] [Abstract][Full Text] [Related]
16. Anti-Yo antibody uptake and interaction with its intracellular target antigen causes Purkinje cell death in rat cerebellar slice cultures: a possible mechanism for paraneoplastic cerebellar degeneration in humans with gynecological or breast cancers.
Greenlee JE; Clawson SA; Hill KE; Wood B; Clardy SL; Tsunoda I; Carlson NG
PLoS One; 2015; 10(4):e0123446. PubMed ID: 25885452
[TBL] [Abstract][Full Text] [Related]
17. [Paraneoplastic cerebellar degeneration--characterization of anti-Yo antibody and underlying cancer].
Tanaka K; Tanaka M; Onodera O; Tsuji S
Rinsho Shinkeigaku; 1995 Jul; 35(7):770-4. PubMed ID: 8777801
[TBL] [Abstract][Full Text] [Related]
18. An interferon-gamma ELISPOT and immunohistochemical investigation of cytotoxic T lymphocyte-mediated tumour immunity in patients with paraneoplastic cerebellar degeneration and anti-Yo antibodies.
Sutton IJ; Steele J; Savage CO; Winer JB; Young LS
J Neuroimmunol; 2004 May; 150(1-2):98-106. PubMed ID: 15081253
[TBL] [Abstract][Full Text] [Related]
19. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
Storstein A; Krossnes BK; Vedeler CA
Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
[TBL] [Abstract][Full Text] [Related]
20. [Importance of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration].
Basić-Jukić N; Kes P; Basić-Kes V; Brunetta B
Acta Med Croatica; 2004; 58(1):63-6. PubMed ID: 15125396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
